Adverse events354

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 354

Type	Event	Organ system	Group	Affected	At risk
other	Dizziness	Nervous system disorders	Placebo - Double Blind (DB) Phase (Titration Plus Maintenance)	12	179
other	Dizziness	Nervous system disorders	Placebo - Transition Phase	16	147
other	Dizziness	Nervous system disorders	Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	31	181
other	Dizziness	Nervous system disorders	Retigabine 200 mg TID - Transition Phase	3	132
other	Dizziness	Nervous system disorders	Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	46	178
other	Dizziness	Nervous system disorders	Retigabine 300 mg TID - Transition Phase	10	114
other	Somnolence	Nervous system disorders	Placebo - Double Blind (DB) Phase (Titration Plus Maintenance)	18	179
other	Somnolence	Nervous system disorders	Placebo - Transition Phase	9	147
other	Somnolence	Nervous system disorders	Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	26	181
other	Somnolence	Nervous system disorders	Retigabine 200 mg TID - Transition Phase	3	132
other	Somnolence	Nervous system disorders	Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	46	178
other	Somnolence	Nervous system disorders	Retigabine 300 mg TID - Transition Phase	12	114
other	Headache	Nervous system disorders	Placebo - Double Blind (DB) Phase (Titration Plus Maintenance)	26	179
other	Headache	Nervous system disorders	Placebo - Transition Phase	8	147
other	Headache	Nervous system disorders	Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	20	181
other	Headache	Nervous system disorders	Retigabine 200 mg TID - Transition Phase	4	132
other	Headache	Nervous system disorders	Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	31	178
other	Headache	Nervous system disorders	Retigabine 300 mg TID - Transition Phase	7	114
other	Fatigue	General disorders	Placebo - Double Blind (DB) Phase (Titration Plus Maintenance)	5	179
other	Fatigue	General disorders	Placebo - Transition Phase	2	147

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00235755/events

API reference For AI assistants

Adverse events354

Sources 3

Read this list from software.